Serum prostate-specific antigen (PSA) testing has been take for worldwide as a screening and diagnostic tool for PCa management [2]; however, the sensitivity and specificity of serum PSA levels are limited, as many factors, for instance age, obesity, prostate volume (PV), and benign prostate diseases, may significantly affect PSA levels [3]. This evidence concerns the gene KLK3 and obesity due to melanocortin 4 receptor deficiency.